Clinical Trial Enzyme Application Targeting Venous Leg Ulcers

Summary

This is an adaptive open-label, first-in-human (Phase IIa) study designed to assess the safety (and efficacy) of Aurase Wound Gel, an enzymatic debridement product, intended for topical application to sloughy venous leg ulcers (VLU)

Timeline

Start

2021-08-09

Primary completion

2023-02-06

Completion

2023-02-06

Outcome

Met primary endpoint

release “SolasCure’s CLEANVLU Phase IIa clinical trial met its primary endpoint; a successful evaluation of safety with no evidence of systemic absorption” solascure.com ↗

Drugs

Indications